Ohcanbohtosat - Rastislav Bahleda

  • Čájehuvvo 1 - 17 / 17
Aiddostahte ozu
  1. 1
    Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review

    Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review Dahkki Matthieu Roulleaux Dugage, Elise F. Nassif, Antoîne Italiano, Rastislav Bahleda

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

    Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors Dahkki Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, Yohann Loriot, Ken A. Olaussen, Christophe Massard, Luc Friboulet

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

    Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors Dahkki Rastislav Bahleda, Funda Meric‐Bernstam, Lipika Goyal, Ben Tran, Yi He, Ikuo Yamamiya, Karim A. Benhadji, Ignacio Matos, Hendrik‐Tobias Arkenau

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

    Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor Dahkki Clémence Hénon, Jean‐Yves Blay, Christophe Massard, Olivier Mir, Rastislav Bahleda, Sarah Dumont, Sophie Postel‐Vinay, Julien Adam, Jean‐Charles Soria, Axel Le Cesne

    Almmustuhtton 2019
    Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors Dahkki Cristiana Sessa, Patricia LoRusso, Anthony W. Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat‐Follet, Jean‐Charles Soria

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

    Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi... Dahkki Valentine M. Macaulay, Mark R. Middleton, Andrew Protheroe, Anthony W. Tolcher, Véronique Dièras, Cristiana Sessa, Rastislav Bahleda, Jean‐Yves Blay, Patricia LoRusso, D. Méry-Mignard, Jean‐Charles Soria

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring<i>FGF</i>/<i>FGFR</i>Aberrations: A Phase I Dose-Expansion Study

    Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring<i>FGF</i>/<i>FGFR</i>Aberrations: A Phase I Dose-Expansion Study Dahkki Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

    Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib Dahkki Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell, Dana Gaffney, Joseph Portale, Ademi Santiago-Walker, Christopher Moy, Peter King, Michael Sharp, Rastislav Bahleda, Feng Luo, John Alvarez, Matthew V. Lorenzi, Suso Platero

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

    Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial Dahkki A. Dimitrios Colevas, Rastislav Bahleda, Fadi Braiteh, Ani Sarkis Balmanoukian, Irene Braña, Nicole G. Chau, Indrani Sarkar, Luciana Molinero, William Grossman, Fairooz F. Kabbinavar, Marcella Fassò, Carol O’Hear, John D. Powderly

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

    Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors Dahkki Rastislav Bahleda, Antoîne Italiano, Cinta Hierro, Alain C. Mita, Andrés Cervantes, Nancy Chan, Mark M. Awad, Emiliano Calvo, Víctor Moreno, Ramaswamy Govindan, Alexander I. Spira, Martha Gonzalez, Bob Zhong, Ademi Santiago-Walker, Italo Poggesi, Trilok Parekh, Hong Xie, Jeffrey R. Infante, Josep Tabernero

    Almmustuhtton 2019
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Understanding and Overcoming Resistance to Selective FGFR inhibitors Across <i>FGFR2</i>-Driven Malignancies

    Understanding and Overcoming Resistance to Selective FGFR inhibitors Across <i>FGFR2</i>-Driven Malignancies Dahkki Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoîne Italiano, Cristina Smolenschi, Lambros Tselikas, Jean–Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, Luc Friboulet

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer

    Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer Dahkki Francesco Facchinetti, Antoine Hollebecque, Floriane Brayé, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cédric Pobel, Ludovic Bigot, Olivier Déas, Juan David Florez Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey I. Nikolaev, Jean–Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A. Olaussen, Yohann Loriot, Luc Friboulet

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

    A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors Dahkki Jean‐Charles Soria, Hui Gan, Sarah P. Blagden, Ruth Plummer, H.T. Arkenau, Marie Ranson, T.R. Jeffry Evans, Gérard Zalcman, Rastislav Bahleda, Antoine Hollebecque, Charlotte Lemech, Emma Dean, Jennifer Brown, D. Gibson, Vijay Peddareddigari, Sonya R Murray, Noelia Nebot, Jolly Mazumdar, Leslie Swartz, K R Auger, Ronald A. Fleming, R. Singh, Michael Millward

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

    Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial Dahkki Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol, Julien Mazières, Josiane Otto, P.-J. Souquet, Rastislav Bahleda, Marie Wislez, Gérard Zalcman, Sophie de Guibert, Fabrice Barlési, B. Mennecier, I. Monnet, Renaud Sabatier, S. Bota, Cathérine Dubos, Véronique Verrièle, Véronique Haddad, G. Ferretti, Alexis B. Cortot, Florence de Fraipont, Marta Jimenez, Natalie Hoog-Labouret, Gilles Vassal

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs

    Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs Dahkki Clémence Hénon, Julien Vibert, Thomas Eychenne, Nadège Gruel, Léo Colmet-Daage, Carine Ngo, Marlène Garrido, Nicolas Dorvault, Maria Eugénia Marques Da Costa, Virginie Marty, Nicolas Signolle, Antonin Marchais, Noé Herbel, Asuka Kawai-Kawachi, Madison M. Lenormand, Clémence Astier, Roman M. Chabanon, Benjamin Verret, Rastislav Bahleda, Axel Le Cesne, Fatima Mechta‐Grigoriou, Matthieu Faron, Charles Honoré, Olivier Delattre, Joshua J. Waterfall, Sarah Watson, Sophie Postel‐Vinay

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

    High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial Dahkki Christophe Massard, Stefan Michiels, Charles Ferté, Marie‐Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loïc Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari, Maud Ngo‐Camus, Rastislav Bahleda, Anas Gazzah, Andrea Varga, Sophie Postel‐Vinay, Yohann Loriot, Caroline Even, Ingrid Breuskin, Nathalie Auger, Bastien Job, Thierry de Baère, Frédèric Deschamps, Philippe Vielh, Jean–Yves Scoazec, Vladimir Lazar, Catherine Richon, Vincent Ribrag, Éric Deutsch, Eric Angevin, Gilles Vassal, Alexander M.M. Eggermont, Fabrice André, Jean‐Charles Soria

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

    Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers Dahkki Capucine Baldini, François‐Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise M. Halse, Séverine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martín-Romano, Jean‐Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amélie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel‐Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurélien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean‐Charles Soria, Christophe Massard, Aurélien Marabelle

    Almmustuhtton 2022
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: